The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 36, No. 1, pp. 93-101. DOI 10.1345/aph.1A033
© 2002 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chong, P.
Right arrow Articles by Yim, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chong, P.
Right arrow Articles by Yim, B.

Research Articles

Rosuvastatin for the treatment of patients with hypercholesterolemia

PH Chong and BT Yim

OBJECTIVE: To review the currently available information on rosuvastatin in the treatment of primary hypercholesterolemia. DATA SOURCES: MEDLEY (2000-January 2001), MEDLIT, MEDLINE, EMBASE, SciSearch, Current Contents, Derwent, Drug, BIOSIS, Adis LMS Drug Alerts, and International Pharmaceutical Abstracts (1994-July 2001) were searched; unpublished data obtained from the manufacturer were also included. STUDY SELECTION: Studies evaluating rosuvastatin including abstracts, proceedings, and data on file from the manufacturer were considered for inclusion. English-language literature was evaluated for pharmacology, pharmacodynamics, pharmacokinetics, therapeutic use, and adverse effects of rosuvastatin. Additional relevant citations were used in the introductory material and discussion section. DATA EXTRACTION: English-language study abstracts selected for inclusion were limited to those on human subjects. Animal data were included only if human data were not available. DATA SYNTHESIS: Resuvastatin, a new synthetic hydroxymethylglutaryl coenzyme A reductase inhibitor (HMG-CoA RI), recently completed Phase III clinical trials. At a dosage of 1-80 mg/d, the drug significantly reduced total cholesterol and low-density-lipoprotein cholesterol (LDL-C) and produced beneficial effects on other lipid parameters as well. Overall, resuvastatin was well tolerated. CONCLUSIONS: In hypercholesterolemic patients, rosuvastatin reduced LDL-C and other lipid parameters to a greater degree than currently available agents. One advantage of rosuvastatin is that it achieves target LDL-C goals in a greater proportion of treated patients with similar adverse events compared with those treated with other HMG-CoA RIs. The potential to reduce risk of coronary heart disease events and decrease mortality as well as cost comparisons with currently used HMG-CoA RIs remains a subject of further investigation.


This article has been cited by other articles:


Home page
 J CARDIOVASC PHARMACOL THERHome page
R. Arora, M. Liebo, and F. Maldonado
Statin-Induced Myopathy: The Two Faces of Janus
Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2006; 11(2): 105 - 112.
[Abstract] [PDF]

Home page
 CirculationHome page
C. J. Vaughan and A. M. Gotto Jr
Update on Statins: 2003
Circulation, August 17, 2004; 110(7): 886 - 892.
[Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2002 by Harvey Whitney Books Company.